PHABRIC
PHArmacy Based Research In Cancer
This study/project is funded by the National Institute for Health Research (NIHR) [This project was funded by NIHR Research for Patient Benefit NIHR203526]. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.
Co-producing Practice Guidelines and Research Recommendations to support Early Diagnosis of Colorectal Cancer in Community Pharmacy
Why Community Pharmacies?
Community pharmacy (CP) plays an important role in illness prevention. A Cochrane Review of CP interventions included 58 randomised controlled trials (RCTs), which focused on diabetes, hypertension, asthma and modification of cardiovascular risk, including approaches to screening and prevention. Health promotion interventions targeting pharmacy users can lead to an improvement in health-related behaviours (e.g., smoking cessation), as well as clinical outcomes, (e.g., a reduction in cholesterol levels). The potential for CP to support the early diagnosis of cancer has only been recognised more recently.
What did we do?
We ran a series of three workshops across two sites (six total) in London and Newcastle. These two areas were chosen to reflect how regional differences in CRC incidence, geography, socioeconomic status, and ethnic background affect individuals’ views about the role of CP in the early diagnosis of cancer. Following the conclusion of the third workshop, we hosted a fourth single site workshop to consolidate practice guidelines and research recommendations across the two regions. All sessions were facilitated by members of the research team, namely the Co-Principal Investigator, Patient and Public Involvement lead and research assistants.
What Comes Next?
This project was funded by NIHR Research for Patient Benefit NIHR203526
